Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)

Drug Name

Beovu (Brolucizumab)

Developer

Novartis

Therapy Class

Anti-vascular endothelial growth factor A (VEGA-A)

Product Description

Intravitreal injection

Current Indication

Wet age-related macular degeneration (AMD)

Market Sector

Ophthalmology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top